Our major milestones include:

  • Engagement of national & global leaders in relevant patent, scientific, clinical, regulatory, business and legal areas of our business
  • Granting of patents in the the United States, Europe (united Kingdom, Germany, France and Italy), Japan, China, India, Brazil, South Africa, Canada, Australia, Hong Kong, Singapore and New Zealand
  • Scientific study results creating new patentable material including the identification of active ingredients and mechanisms of action
  • Award of a scholarship for a Ph D student investigating the active ingredients and properties of OPAL A at Queen Mary College, University of London
  • Commencement of a proof-of-concept clinical trial for the use of OPAL A in the treatment of venous and pressure ulcers at the Heidelberg Repatriation Hospital in Melbourne, with Associate Professor Michael Woodward, recognised as the leading clinical researcher in wounds in Australia, being the principal investigator
  • Execution of our first licensing agreement, confined to Australia, with a significant upfront fee being paid
  • Successful launch of our Australian licensee’s OptiDerma Moisturising Skin Support product into Aged Care Residential facilities in Tasmania, gaining 80% of the market in 15 months